ABSTRACT
Introduction: Polycystic Ovarian Syndrome was originally described in seven women in whom the syndrome could at best be described as the combination of hirsutism, obesity, amenorrhea, and enlarged bilateral polycystic ovaries.(1) Since then, our understanding of PCOS has evolved so far that none of the originally described features is considered to be a consistent finding in PCOS—not even the appearance of numerous tiny ovarian “cysts” for which the syndrome was named.(2) Materials and Methods: After obtaining approval of the ethics committee, a prospective, randomized, clinical controlled study was conducted for 1 and 1/2 years. Patients were randomly allocated to one of the two groups, group D (n=50), received oral Tab Metformin 500mg BD, Tab Calcium 500mg OD, Tab Vitamin–D–1000 IU OD for 3months and group M (n=50), received oral Tab Metformin 500mg BD for 3months. Age, Menstrual irregularties, BMI, Hirsutism score Cases with hirsutism score >8, Acne, Alopesia, USG ovarian volume, S.LH, S.FSH, S. Total Calcium, S. Vitamin D and Free insulin were recorded both before treatment and after treatment in both groups. Patients were also observed for adverse reaction. Data was statistically analyzed using Epi info 7 computer software version: 7.2.1.0. Results: Both groups were comparable with regard to demographic characteristics (p>0.05). There was statistically significant difference between the two groups regarding Body Mass Index, USG ovarian volume and S.Vitamin D. However there was no statistically significant difference between the two groups regarding Menstrual irregularties, Hirsutism score Cases with hirsutism score >8, Acne, Alopesia, S.LH, S.FSH, S. Total Calcium and Free insulin. Conclusion: This study showed the positive effects of metformin, calcium & vitamin D supplementation on Body Mass Index, Serum Vitamin D and Ovarian volume in women with polycystic ovary syndrome.